30 April 2024
Argent BioPharma Ltd
PDMR Notification
Argent BioPharma Ltd (Argent BioPharma, RGT or the Company), wishes to advise that the following Persons Discharging Managerial Responsibilities (PDMR) were issued a combined 68,000 unlisted options. This notification is made in accordance the UK Market Abuse Regulations.
| 1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
| (a) | Name | Amir Polak | |||
| 2 | Reason for the notification
| ||||
| (a) | Position
| Chief Pharmaceutical Development Officer | |||
| (b) | Initial notification/amendment
| Initial | |||
| (c) | If amendment: reason
| n/a | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| | Full name of entity | Argent BioPharma Ltd
| |||
| | Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
| (a) | Description of the financial instrument, type of instrument | Unlisted options exercisable at A$0.70 on or before 1 April 2029. | |||
| (b) | Identification Code (ISIN)
| AU0000326647 | |||
| (c) | Nature of transaction | Grant of Options over Ordinary Shares | |||
| (d) | Currency | Price | Volume | Total | |
| | AUD | 0.00 | 12,000 | N/A | |
| | Aggregated information | ||||
| | AUD | 0.00 | 12,000 | N/A | |
| (e) | Date of transaction
| 26 April 2024 | |||
| (f) | Place of transaction
| Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
| (a) | Name | Yair Tal | |||
| 2 | Reason for the notification
| ||||
| (a) | Position
| Chief Information Security Officer | |||
| (b) | Initial notification/amendment
| Initial | |||
| (c) | If amendment: reason
| n/a | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| | Full name of entity | Argent BioPharma Ltd
| |||
| | Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
| (a) | Description of the financial instrument, type of instrument | Unlisted options exercisable at A$0.70 on or before 1 April 2029. | |||
| (b) | Identification Code (ISIN)
| AU0000326647 | |||
| (c) | Nature of transaction | Grant of Options over Ordinary Shares | |||
| (d) | Currency | Price | Volume | Total | |
| | AUD | 0.00 | 8,000 | N/A | |
| | Aggregated information | ||||
| | AUD | 0.00 | 8,000 | N/A | |
| (e) | Date of transaction
| 26 April 2024 | |||
| (f) | Place of transaction
| Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
| (a) | Name | Yifat Steuer | |||
| 2 | Reason for the notification
| ||||
| (a) | Position
| Chief Operating Officer and Deputy CEO | |||
| (b) | Initial notification/amendment
| Initial | |||
| (c) | If amendment: reason
| n/a | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| | Full name of entity | Argent BioPharma Ltd
| |||
| | Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
| (a) | Description of the financial instrument, type of instrument | Unlisted options exercisable at A$0.70 on or before 1 April 2029. | |||
| (b) | Identification Code (ISIN)
| AU0000326647 | |||
| (c) | Nature of transaction | Grant of Options over Ordinary Shares | |||
| (d) | Currency | Price | Volume | Total | |
| | AUD | 0.00 | 15,000 | N/A | |
| | Aggregated information | ||||
| | AUD | 0.00 | 15,000 | N/A | |
| (e) | Date of transaction
| 26 April 2024 | |||
| (f) | Place of transaction
| Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
| (a) | Name | Itay Nissim | |||
| 2 | Reason for the notification
| ||||
| (a) | Position
| Chief Supply Chain Officer | |||
| (b) | Initial notification/amendment
| Initial | |||
| (c) | If amendment: reason
| n/a | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| | Full name of entity | Argent BioPharma Ltd
| |||
| | Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
| (a) | Description of the financial instrument, type of instrument | Unlisted options exercisable at A$0.70 on or before 1 April 2029. | |||
| (b) | Identification Code (ISIN)
| AU0000326647 | |||
| (c) | Nature of transaction | Grant of Options over Ordinary Shares | |||
| (d) | Currency | Price | Volume | Total | |
| | AUD | 0.00 | 12,000 | N/A | |
| | Aggregated information | ||||
| | AUD | 0.00 | 12,000 | N/A | |
| (e) | Date of transaction
| 26 April 2024 | |||
| (f) | Place of transaction
| Outside a trading venue | |||
-Ends-
Authorised for release by the Company Secretary, for further information please contact:
| Argent BioPharma Limited Roby Zomer CEO & Managing Director +61 8 6555 2950
| Argent BioPharma Limited Rowan Harland Company Secretary +61 8 6555 2950
|
| UK IR/PR Advisers IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen +44 203 934 6630 | UK Brokers Oberon Capital Aimee McCusker / Adam Pollock +44 203 179 5300 aimeemccusker@oberoninvestments.com adampollock@oberoninvestments.com |
About Argent BioPharma
Argent BioPharma purpose is to address unmet medical needs through the pioneering integration of Nanotechnology and Multidisciplinary research methods. Our approach heralds a transformative shift in healthcare, combining the power of multi-targeted drug therapies with precision nanoscale delivery to enhance treatment efficacy while reducing side effects. Central to our ethos is making these innovative treatments accessible, ensuring they reach those underserved by current medical solutions. As we endeavor to become globally recognized in the life science industry, we are committed to bridging healthcare gaps, redefining industry standards, and providing impactful solutions and hope to communities worldwide.
Follow us through our social media channels:
LinkedIn: Argent BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent BioPharma
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.